Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study

20251 citationsJournal Articlehybrid Open Access

Authors

Monica Luque · Spital Thurgau (Switzerland)

Kristina Zhelyazkova · Spital Thurgau (Switzerland)

Laxmikant Vashishta · Spital Thurgau (Switzerland)

Masna Rai · Spital Thurgau (Switzerland)

Abid Sattar · Spital Thurgau (Switzerland)

Katarina Petrović · Spital Thurgau (Switzerland)

Richard Bucknall

Abstract

The trial is registered at ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT05842213) and the EU Clinical Trials Register (EudraCT Number: 2022-001825-63).

Topics & Keywords

Publication Details

Published in: BioDrugs

Volume 40, Issue 1, pp. 135-149

DOI: 10.1007/s40259-025-00748-8

Field-Weighted Citation Impact: 0.84

Command Palette

Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study

Authors

Abstract

Topics & Keywords

Publication Details